Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases
NCT ID: NCT01597128
Last Updated: 2017-03-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2011-03-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias
NCT01987700
A Comparison of the Outcomes in Fortiva and Strattice Mesh
NCT05572021
A Comparison of Fortiva and Strattice Tissue Matrices in Complex, Ventral Hernia Repair
NCT02587403
RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
NCT02228889
Repair of Infected or Contaminated Hernias
NCT00617357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Musculoskeletal Transplant Foundation (MTF) has manufactured and processed Flex HD Acellular Hydrated Dermis. This acellular dermis is derived from human skin. In complicated ventral hernia repairs, this type of graft tissue is necessary. Flex HD has been shown to reduce operative time, lower operative costs and provides minimal elasticity.
The Musculoskeletal Transplant Foundation (MTF) is a non-profit service organization dedicated to providing quality allograft tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. MTF is a national consortium comprised of academic medical institutions, organ procurement organizations and tissue recovery organizations. From their inception, they have been both donor-focused and surgeon-driven. Since their inception in 1987, MTF has recovered more than 60,000 donors and distributed more than 3 million grafts for transplantation.
The Foundation was established by surgeons and teaching institutions to meet the need for a high quality and consistent allograft supply.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flex HD
Mesh Type
Flex HD
Flex HD mesh for hernia repair
Strattice
Use of a second mesh type
Strattice
Strattice mesh for hernia repair
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flex HD
Flex HD mesh for hernia repair
Strattice
Strattice mesh for hernia repair
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a ventral or incisional hernia with at least one of the following characteristics
* Hernia is at least 6cm in transverse dimension
* History of 2 or more prior ventral or incisional hernia repairs
* Active or prior infection of the abdominal wall
* Enterocutaneous fistula to the anterior abdominal wall
* Mesh requiring mesh removal which would result in a hernia at least 6cm in transverse dimension
* Patients is scheduled to undergo component separation hernia repair
* Have an ASA Score of 3 or less
* Have a BMI between 20 and 55
* Be a candidate for primary approximation of skin and wound following hernia repair
* Have a life expectancy of at least 2 years
Exclusion Criteria
* Be a candidate for emergency surgery that would make giving valid Informed Consent impractical
* Be currently taking part in another clinical study that conflicts with the current study
* Have active generalized peritonitis or intraperitoneal sepsis
* Have active necrotizing fasciitis
* Have active abdominal compartment syndrome
* Have active untreated metabolic or systemic illness
* Have known active malignancy present
* Be unable to give valid informed consent or comply with required follow-up schedule
* Suffer from mental capacity sufficiently severe to make informed consent unobtainable
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
John Roth
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Roth
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John S Roth, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky Medical Center
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Musculoskeletal Transplant Foundation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-0080-P6A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.